Rab 26 CRISPR Activation Plasmid (h): sc-411810-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Rab 26 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- Rab 26 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by Rab 26 CRISPR Activation Plasmid (h) and Rab 26 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the RAB26 transcriptional start site. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Rab 26 CRISPR Activation Plasmid (h) | sc-411810-ACT | 20 µg | $397.00 | |||
Rab 26 CRISPR Activation Plasmid (h2) | sc-411810-ACT-2 | 20 µg | $397.00 |
RAB26 encodes Rab 26, a small Rab family GTPase that regulates membrane trafficking by coordinating vesicle budding, transport, and fusion events. Rab 26 has been linked to secretory and endolysosomal processes, including routing of cargo through recycling and degradative pathways and modulation of vesicle dynamics in specialized cell types. By influencing the spatial organization of trafficking machinery and compartment identity, RAB26 can affect signaling output and cellular homeostasis. Dysregulated Rab GTPase–dependent trafficking has been associated with neurodegenerative phenotypes, cancer cell behavior, and immune dysfunction, making RAB26 a relevant node for studying pathway perturbations in disease-relevant models.
Rab 26 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous RAB26 expression without altering the underlying DNA sequence.
Rab 26 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the RAB26 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the RAB26 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Rab 26 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native RAB26 locus and enabling the study of Rab 26-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Rab 26 pathway restoration in tumor cells with silenced or reduced RAB26 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.